Soberana 01 Uses, Dosage, Side Effects and more
Soberana 01, also known as Soberana 01, is a vaccine candidate for COVID-19 that is being led developmentally by the Finlay Vaccine Institute. It is currently being tested in the clinical trial RPCEC00000332 (Phase I / II, randomized, controlled, adaptive, double-blind and multicenter study to evaluate the safety, reactogenicity and immunogenicity, of the prophylactic Soberana 01 anti-SARS-CoV-2 Vaccine Candidate in a two-doses schedule. (COVID-19) - SOBERANA 01).
| Trade Name | Soberana 01 |
| Generic | FINLAY-FR-1 |
| FINLAY-FR-1 Other Names | FINLAY-FR-1 anti-SARS-CoV-2 vaccine candidate, Soberana 01 |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
